UPDATE: Puma Biotech (PBYI) Sees Heavy Selling Pressure; SABCS Abstracts Released

Puma Biotechnology (PBYI) Abstract Data Helps Explain Need to Change Trial - RBC

RBC Capital analyst Simos Simeonidis weighed in on Sector Perform-rated Puma Biotechnology (NYSE: PBYI) amid SABCS loperamide prophylaxis data show a higher than expected Grade 3 diarrhea rate. He said the data helps eplains the need to try new regimen.

commented, ". In an abstract released this morning, Puma disclosed data from the Phase II CONTROL trial in the extended adjuvant setting showing that treatment with loperamide helps lower the ~40%... More

Stifel Says Puma Biotechnology (PBYI) Abstract Somewhat Concerning, But Sell-Off Appears to be an Over Reaction

Stifel analyst Thomas Shrader weighed in on Puma Biotechnology (NYSE: PBYI) after the company's San Antonio abstract is out and the diarrhea rate for the complete CONTROL trial looks about twice what was indicated in the early look (27% (n=133) vs. 16% (n=50)).

Shrader commented, "This is somewhat disturbing as this abstract... More

Puma Biotech (PBYI) Said Defended at Citi

Puma Biotech (NYSE: PBYI) Said Defended at Citi

Puma Biotech (PBYI) Defended at Citi

Puma Biotech (NYSE: PBYI) defended at Citi following massive sell-off on abstract data.

Puma Biotech (PBYI) Halted on Circuit Breaker

Puma Biotech (NYSE: PBYI) Halted on Circuit Breaker